Aura Biosciences Posts $0.29 GAAP Loss Per Share for Q3 2026

Your call?🐂 Bullish🐻 Bearish

The company had $297.2 million in cash, cash equivalents and marketable securities as of Sept. 30 and said it believes those resources can fund operations into the first half of 2029.